hydroxychloroquine sulfate tablet
1 INDICATIONS AND USAGE Hydroxychloroquine Sulfate Tablets are an antiMalarial and antirheumatic indicated for the: Treatment of uncomplicated Malaria due to Plasmodium falciparum, Plasmodium Malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. (1.1) Prophylaxis of Malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. (1.1) Treatment of Rheumatoid Arthritis in adults. (1.2) Treatment of systemic Lupus erythematosus in adults. (1.3) Treatment of chronic discoid Lupus erythematosus in adults. (1.4) Limitations of Use (1.1): Hydroxychloroquine Sulfate Tablets are not recommended for the: Treatment of complicated Malaria. Treatment of chloroquine or hydroxychloroquine-resistant strains of Plasmodium species. Treatment of Malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Prophylaxis of Malaria in geographic areas where chloroquine resistance occurs. Prevention of relapses of P. vivax or P. ovale because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline drug is necessary. 1.1 Malaria Hydroxychloroquine sulfate tablets are indicated in adult and pediatric patients for the: Treatment of uncomplicated Malaria due to Plasmodium falciparum, Plasmodium Malariae, Plasmodium vivax, and Plasmodium ovale . Prophylaxis of Malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use: Hydroxychloroquine sulfate tablets are not recommended for: Treatment of complicated Malaria. Treatment of Malaria by chloroquine or hydroxychloroquine-resistant strains of Plasmodium species [see Microbiology(12.4)] . Treatment of Malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Prophylaxis of Malaria in geographic areas where chloroquine resistance occurs. Prevention of relapses of P. vivax or P. ovale because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline drug is necessary [ see Microbiology (12.4)]. For the most current information about drug resistance, refer to the latest recommendations from the Center for Disease Control and Prevention 1 . 1.2 Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic Rheumatoid Arthritis in adults. 1.3 Systemic Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of systemic Lupus erythematosus in adults. 1.4 Chronic Discoid Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid Lupus erythematosus in adults.
dr. reddy's laboratories inc.
OVAL WHITE AC384
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied
HYDROXYCHLOROQUINE SULFATE Tablets, USP are white to off-white, capsule shaped film-coated tablets debossed with “A1” on one side and plain on the other side. Each film-coated tablet contains
HYDROXYCHLOROQUINE SULFATE, USP 100 mg (equivalent to 77.5 mg base). Bottles of 100 tablets NDC: 43598-133-01 Bottles of 500 tablets NDC: 43598-133-05
HYDROXYCHLOROQUINE SULFATE Tablets, USP are white to off-white, capsule shaped film-coated tablet debossed with “AC 384” on one side and plain on the other side. Each film-coated tablet contains
HYDROXYCHLOROQUINE SULFATE, USP 200 mg (equivalent to 155 mg base). Bottles of 100 tablets NDC: 43598-721-01, Bottles of 500 tablets NDC: 43598-721-05
HYDROXYCHLOROQUINE SULFATE Tablets, USP are yellow to pale yellow colored, capsule shaped, film-coated tablets debossed with “A3” on one side and plain on the other side. Each film-coated tablet contains
HYDROXYCHLOROQUINE SULFATE, USP 300 mg (equivalent to 232.5 mg base). Bottles of 100 tablets NDC: 43598-132-01 Bottles of 500 tablets NDC: 43598-132-05
HYDROXYCHLOROQUINE SULFATE Tablets, USP are white to off-white, capsule shaped, film-coated tablets debossed with “A4” on one side and plain on the other side. Each film-coated tablet contains
HYDROXYCHLOROQUINE SULFATE, USP 400 mg (equivalent to 310 mg base). Bottles of 100 tablets NDC: 43598-131-01 Bottles of 500 tablets NDC: 43598-131-05 16.2 Storage Dispense in a tight, light-resistant container as defined in the USP/NF. Store at room temperature [20° to 25°C (68° to 77°F), allow for excursions between 15° and 30°C (59° and 86°F)].
More pills like OVAL AC384